Journal: BMC Cancer

Article Title: Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

doi: 10.1186/s12885-025-14657-0

Figure Lengend Snippet: Synergistic inhibition of proliferation of MDS cells by azacitidine and SMI-16a. a The IC 50 values of azacitidine and SMI-16a against MDS cells were determined to be 20 nM and 25 µM, respectively. b Combination therapy with azacitidine and SMI-16a significantly suppressed cell proliferation compared to monotherapy. c Combination effects were evaluated using the CalcuSyn software, with combination index (CI) < 1 indicating synergy, CI = 1 indicating additivity, and CI > 1 indicating antagonism

Article Snippet: Azacitidine and SMI-16a (a PIM-2 inhibitor) were supplied by MedChemExpress (Monmouth Junction, NJ, USA) and stored as stock solutions at − 80 °C.

Techniques: Inhibition, Software

Journal: BMC Cancer

Article Title: Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

doi: 10.1186/s12885-025-14657-0

Figure Lengend Snippet: Combination of azacitidine and SMI-16a induces cell apoptosis. A Apoptosis was assessed using propidium iodide (PI) and annexin V staining followed by flow cytometry after 48 h of treatment. B TUNEL assay results for MDS cell lines, including quantitative analysis of TUNEL-positive cells. C Western blot analysis showing upregulation of the apoptosis-associated proteins PARP and cleaved caspase-3. * indicates a significant difference compared with the control ( P < 0.05) and ** indicates a significant difference compared with monotherapy ( P < 0.05)

Article Snippet: Azacitidine and SMI-16a (a PIM-2 inhibitor) were supplied by MedChemExpress (Monmouth Junction, NJ, USA) and stored as stock solutions at − 80 °C.

Techniques: Staining, Flow Cytometry, TUNEL Assay, Western Blot, Control

Journal: BMC Cancer

Article Title: Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

doi: 10.1186/s12885-025-14657-0

Figure Lengend Snippet: Inhibition of NF-κB pathway-related protein expression by azacitidine and SMI-16a. a Western blot analysis demonstrating downregulation of phosphorylated p65 (p-p65) and phosphorylated IκB (p-IκB) expression. b Western blot analysis showing downregulation of survivin and Bcl-2 expression

Article Snippet: Azacitidine and SMI-16a (a PIM-2 inhibitor) were supplied by MedChemExpress (Monmouth Junction, NJ, USA) and stored as stock solutions at − 80 °C.

Techniques: Inhibition, Expressing, Western Blot

Journal: BMC Cancer

Article Title: Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition

doi: 10.1186/s12885-025-14657-0

Figure Lengend Snippet: Azacitidine and SMI-16a induce apoptosis in primary CD34 + cells. a Schematic diagram of drug treatment of primary CD34 + cells. The illustration was created with BioRender.com. b Induction of apoptosis in primary CD34 + cells by azacitidine and SMI-16a. Primary CD34 + cells obtained from patients with high-risk MDS and AML were treated with azacitidine and SMI-16a for 24 h. The combination of these two drugs induced apoptosis in CD34 + cells

Article Snippet: Azacitidine and SMI-16a (a PIM-2 inhibitor) were supplied by MedChemExpress (Monmouth Junction, NJ, USA) and stored as stock solutions at − 80 °C.

Techniques: